Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine.
|
|
- Brice Robinson
- 5 years ago
- Views:
Transcription
1 Eur Respir J 1997; 10: DOI: / Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine A. Noseda*, J.-P. Carpiaux*, C. Markstein**, A. Meyvaert +, V. de Maertelaer ++ Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. A. Noseda, J.-P. Carpiaux, C. Markstein, A. Meyvaert, V. de Maertelaer. ERS Journals Ltd ABSTRACT: The purpose of this placebo-controlled, double-blind, randomized study was to assess the effect of nebulized morphine on dyspnoea perceived at rest by patients with advanced disease. Seventeen hospital in-patients with disabling dyspnoea received isotonic saline or morphine via nebulization for 10 min through a mouthpiece, combined with oxygen via nasal prongs. On four consecutive days, they were given one of the four following treatments in random order: saline with 2 L min -1 oxygen; 10 mg morphine with 2 L min -1 oxygen; 20 mg morphine with 2 L min -1 oxygen; and 10 mg morphine without oxygen (prongs fixed, no flow). Dyspnoea was assessed on a bipolar visual analogue scale (VAS) (-100% much more short of breath, +100% much less short of breath), and arterial oxygen saturation (Sa,O 2 ) and respiratory frequency (f R) were recorded at the end of nebulization and 10 min later. In 14 subjects who completed the study, mean VAS ratings 10 min after the end of nebulization ranged +30 to +43%, with no significant difference between the four study days (VAS 20 mg morphine minus VAS saline, 95% confidence interval (95% CI) -6 to +8%). Sa,O 2 significantly increased on the 3 days with supplemental oxygen, and remained stable on the zero flow day. Respiratory frequency significantly decreased on the 4 days, with a trend to correlation between VAS rating and parallel change in respiratory frequency (Spearman's rank correlation coefficient (r s )=-0.46; p=0.09). We conclude that the subjects benefited from saline or morphine via a placebo effect and/or a nonspecific effect, and that nebulized morphine had no specific effect on dyspnoea. Eur Respir J 1997; 10: *Dept of Medicine, Pulmonary Division, **Palliative Care Support Team and + Pharmacy, Hôpital Universitaire Brugmann, Brussels, Belgium, ++ Medical Statistical Unit, IRIBHN, Campus Erasme, Université Libre de Bruxelles, Brussels, Belgium. Correspondence: A. Noseda Dept of Medicine Pulmonary Division Hôpital Universitaire Brugmann Place A. Van Gehuchten 4 B-1020 Brussels Belgium Keywords: Dyspnoea nebulized morphine visual analogue scale Received: June Accepted after revision January Disabling dyspnoea associated with severe lung or heart disease is often inadequately controlled, even with maximal treatment of the underlying condition. Systemic treatment with opioids has been reported to reduce dyspnoea in some patients groups [1, 2], but adverse effects are common and preclude their long-term use. Nebulized morphine is potentially attractive, since it is free of the adverse effects associated with systemic therapy and uncontrolled studies have suggested a beneficial effect on dyspnoea [3, 4]. The present study tested the hypothesis that opioidsensitive receptors located in the respiratory tract [5] modulate dyspnoea perceived at rest by patients with advanced lung or heart disease. Hospital in-patients with disabling dyspnoea were, in a double-blind randomized protocol, given nebulized isotonic saline or nebulized morphine (10 or 20 mg) and the change in perceived shortness of breath was recorded on a bipolar visual analogue scale (VAS). Subjects and methods Study design On four consecutive days, each subject received the four following treatments in random order: nebulized isotonic saline with oxygen; 10 mg nebulized morphine with oxygen; 20 mg nebulized morphine with oxygen; and 10 mg nebulized morphine without oxygen. The primary outcome variable was dyspnoea, rated on a bipolar VAS; additional variables were arterial oxygen saturation (Sa,O 2 ) and respiratory frequency (f R). The protocol was approved by the Ethics Committee of the Hôpital Brugmann, and each subject gave informed consent. Subjects All subjects were hospital in-patients with severe lung or heart disease. Criteria for entry into the study were: 1) distressing dyspnoea not relieved by conventional medical therapy, (i.e. maximal treatment of underlying pulmonary and/or cardiac disease, including management of pleural effusion, when present); and 2) ability to rate dyspnoea on a VAS, as judged from normal cognitive function (Mini-Mental State Questionnaire Score of at least 24/30) [6], and specific understanding of the scale used in this study. Seventeen patients (13 males and 4 females) were studied. Their anthropometric and clinical features are presented in table 1. The most frequent diagnosis (12 subjects) was chronic obstructive pulmonary disease (COPD);
2 1080 A. NOSEDA ET AL. Table 1. Anthropometric and clinical features of 17 patients with advanced disease and disabling dyspnoea Pt Sex Age Height Weight Main Additional VC FEV1 No. yrs cm kg diagnosis # diagnosis L L 1 M COPD M COPD F COPD M COPD Talc pleurodesis F COPD Anaemia M COPD F COPD F IPF M COPD Heart failure M COPD M Malignancy Left pneumonectomy M COPD M Heart failure NA NA 14 M Malignancy Talc pleurodesis NA NA 15 M Malignancy Talc pleurodesis NA NA 16 M COPD Heart failure M COPD Mean SD # : Main diagnosis responsible for dyspnoea; : additional diagnosis likely to contribute to dyspnoea. Pt: patient; M: male; F: female; VC: vital capacity; FEV1: forced expiratory volume in one second; COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis; NA: not available. one of these patients had undergone talc pleurodesis for recurrent pneumothoraces. Of three subjects with malignancy as main diagnosis, one had recurrence of lung cancer on a stump of left pneumonectomy; one had lung cancer with pleural involvement; and one had metastatic pleurisy from unknown primary tumour. The latter two subjects had been managed by tube drainage and talc pleurodesis. Spirometric data were available in 14 subjects and were consistent with severe airflow limitation. The treatments most often prescribed were: inhaled bronchodilators (n=14); oral or i.v. steroids (n=11); oral or i.v. theophylline (n=9), diuretics (n=8); nitrates (n=8); and oxygen (n=8). Steroids were given as a part of therapy for COPD, but also, although less frequently, for adrenal insufficiency (n=1), perimetastatic cerebral oedema (n=1), or hypercalcaemia (n=1). Other treatments included: anticoagulants (n=5); benzodiazepines (n=5); inhaled steroids (n=4); digoxine (n=4); antibiotics (n=4); antidepressants (n=2); analgesics (n=2); and angiotensin converting enzyme (ACE) inhibitor (n=1). Treatment under investigation At time zero, the subject was asked to rest in bed. Oxygen was stopped in those subjects receiving oxygen as a part of in-hospital treatment. At time 15 min, a 4 ml volume was nebulized, using an air-driven 5 L min -1 flow rate for 10 min, and administered to the subject via a mouthpiece. The solution contained either 10 mg morphine chlorhydrate (2 of the 4 days), 20 mg morphine chlorhydrate (1 day), or isotonic saline (1 day). Morphine solutions were stabilized using 1 mg Na 2 S 2 O 5. All solutions were sterile and conserved at 4 C, light-free. All morphine and saline solutions were prepared and coded independently in the hospital pharmacy. Oxygen was delivered at 2 L min -1 via nasal prongs on 3 of the 4 days, including the 20 mg morphine and the saline day. On one of the two 10 mg days, prongs were fixed but no oxygen was given. Outcome variables Dyspnoea was rated on a 40 cm horizontal bipolar VAS labelled "much more short of breath" at the left end, "much less short of breath" at the right end and "no change" in the middle [7]. This scale allows the subject to report either an increase or a decrease in shortness of breath when moving off from the no change midpoint. It is particularly suited for evaluating the response to an acute intervention, and has been validated by our group in patients with chronic respiratory disease [7]. Dyspnoea ratings measured in this way are reported as percentages (range -100 to +100%). Oxygen saturation was monitored using a Biox Ohmeda 3700 pulse oximeter (Madison, USA), with an ear probe. Respiratory rate was measured twice for 1 min, and the two results were averaged. Sa,O 2 and fr were measured at times 15 min (baseline), 25 min (end of nebulization), and 35 min. VAS ratings were recorded at times 25 min and 35 min. Statistical analysis Data were submitted to an analysis of variance (ANOVA) with two repeated measures: one for the treatments (four levels), and one for the time (two or three levels). In the case of significant difference between the treatments, mean contrasts between them were calculated. The study was designed to give a 90% chance of detecting a 25% change in dyspnoea at the 0.05 p- level. Assuming that dyspnoea could be assessed on the bi-polar VAS with a within-subject coefficient of variation of 15% [7], the sample size estimation indicated that at least 13 subjects were required. A p-value of less than 0.05 was considered statistically significant.
3 NEBULIZED MORPHINE AND DYSPNOEA 1081 Table 2. Outcome variables (VAS, Sa,O 2 and f R) for the 14 subjects who completed the study Saline + O 2 10 mg morphine + O 2 20 mg morphine + O 2 10 mg morphine without O min min min min min min min min min min min min VAS rating % (25) (27) (24) (28) (26) (27) (30) (25) Sa,O 2 % (5) (5) (4) (7) (7) (6) (4) (4) (4) (5) (8) (8) fr breaths min (4.0) (3.7) (3.9) (5.6) (5.3) (5.3) (3.8) (4.2) (4.6) (4.1) (3.7) (3.9) Values are presented as mean, and SD in parenthesis. VAS: visual analogue scale; Sa,O 2 : arterial oxygen saturation; f R: respiratory frequency. 15 min: baseline; 25 min: at the end of nebulization; 35 min: 10 min after the end of nebulization. Results Fourteen of the 17 subjects completed the study. Subjects Nos. 6, 11 and 14 died (one with COPD, two with malignancy) on the third or fourth study day; all three deaths occurred during the night, none being related to the present experiment. The results that follow involve the 14 subjects who completed the study. Of the 112 VAS ratings recorded throughout the study, 101 were positive (subject less short of breath), 7 zero (no change), and 4 negative (subject more short of breath). The 11 ratings 0% were obtained after either 10 mg morphine with (n=4) or without (n=5) oxygen, or 20 mg morphine (n=2). No rating 0% was recorded after saline. As shown in table 2, mean VAS ratings at time 25 min (at the end of nebulization) ranged from +23 to +34%. The additional improvement recorded at time 35 min (10 min after the end of nebulization) was significant (p=0.011). VAS ratings recorded at time 35 min are shown in figure 1. No significant difference in effectiveness was detected between the four treatments under investigation (p=0.362). The 95% confidence interval (95% CI) for the difference in VAS rating between the 20 mg morphine day and the saline day was -12 to +6% at time 25 min, and -6 to +8% at time 35 min. Mean baseline Sa,O 2 ranged 90 93% across the four study days (table 2). As expected, oxygen administration significantly increased Sa,O 2 when combined either with saline (p<0.001), 10 mg (p=0.002), or 20 mg morphine (p<0.001). After 10 mg nebulized morphine without supplemental oxygen, Sa,O 2 decreased slightly from 91 (5) to 90 (8) %, but the decrease did not reach significance (p=0.216). At baseline, the subjects were mildly tachypnoeic at rest (mean f R breaths min -1 ). Respiratory frequency significantly decreased over time (p=0.043), and no significant difference was detected between the four treatments (p=0.861). As illustrated in figure 2, there was a tendency for the largest improvements in shortness of breath (at time 35 min) to be associated with the largest decreases in f R. The correlation between the two variables approached significance (Spearman's rank correlation coefficient (r s ) = -0.46; p=0.09). None of the treatments caused any important adverse effect. Four of the 56 experiments were associated with minor manifestations: one subject felt the nebulized solution pricked his throat on the 20 mg morphine day and on the saline day; one subject complained about a bitter taste after 20 mg morphine; and a burst of cough was observed following 20 mg morphine in another subject VAS % Patient No. Fig. 1. Visual analogue scale (VAS) ratings, expressed as a percentage, recorded, at time 35 min, on four consecutive days in 14 patients with disabling dyspnoea, 10 min after the end of: nebulized saline with 2 L min -1 oxygen ( ); 10 mg morphine with 2 L min -1 oxygen ( ); 20 mg morphine with 2 L min -1 oxygen ( ); or 10 mg morphine without oxygen ( ).
4 1082 A. NOSEDA ET AL. VAS rating % f R breaths min -1 Discussion Fig. 2. Visual analogue scale (VAS) ratings recorded at time 35 min, 10 min after the end of nebulized treatment plotted against the parallel changes in respiratory frequency ( f R). The values taken into account were the averages of the four treatments, since no treatment difference was detected either for VAS or f R. A nonparametric correlation analysis was performed (Spearman's rank correlation coefficient (r s ) = -0.46; p=0.09). In this controlled study, we assessed the effect of nebulized morphine on the sensation of dyspnoea experienced by hospital in-patients with advanced disease, and found no difference in efficacy between saline, and 10 mg or 20 mg morphine. The study was originally designed because of recent claims that inhaled opioids are able to relieve severe dyspnoea from malignant or nonmalignant lung disease [3, 4]. Our results do not support the hypothesis that nebulized morphine may decrease dyspnoea through a local action on the airways. In two studies published in the 1980s, a decrease in exercise-induced dyspnoea was obtained in COPD subjects following oral administration of either 15 mg dihydrocodeine [1], or 0.8 mg kg -1 of a morphine solution [2]. However, serious side-effects occurred in the latter study. Since the existence of opioid-sensitive receptors in the respiratory tract has been demonstrated [5], it is not surprising that the potential of inhaled morphine for reducing dyspnoea has elicited several trials. In 1989, YOUNG et al. [8] reported an increase in exercise endurance in COPD patients after a low 5 mg dose of nebulized morphine [8]. However, these authors did not assess dyspnoea, and their results were strongly influenced by a spectacular improvement in one individual. A first claim of a beneficial effect on dyspnoea at rest from a small 5 mg dose of nebulized morphine involved a single patient with mesothelioma, whose dyspnoea was unresponsive to a large 160 mg day -1 oral dose of morphine [3]. In 1994, FARNCOMBE et al. [4] reported a beneficial effect in a group of 54 patients with disabling dyspnoea from either malignant (n=40) or nonmalignant (n=14) disease. Thirty four patients received morphine (5 30 mg), the remainder various other opioids, and 34 of the 54 subjects claimed a decrease in shortness of breath. Although the study was uncontrolled and dyspnoea not quantitated, other groups commented with some enthusiasm about the results on the basis of a similar favourable experience with inhaled morphine [9, 10]. The present study was specifically designed to evaluate the contribution of morphine-sensitive receptors located in the respiratory tract to the sensation of dyspnoea. Isotonic saline was used as placebo, and it was found that dyspnoea, quantitated on a bipolar VAS particularly well-suited to assess the response to an acute intervention, was not reduced to a greater extent following morphine than following saline. The significance of this negative study needs to be discussed. That the dose of nebulized morphine was too small seems an unlikely explanation for the lack of specific effect on dyspnoea, since the 10 and 20 mg doses used compare well with the 5 30 mg claimed to be beneficial in about two thirds of the subjects in the study by FARNCOMBE et al. [4]. That the delay to assess the response was not sufficiently long is no more convincing. Indeed, the mean delay to obtain a peak serum concentration following nebulized morphine is 45 min [11], so that we deliberately chose to record the response on the bipolar VAS after 10 and 20 min, as the study aimed to specifically evaluate the intrapulmonary action of nebulized morphine. That the scale used to assess a change in shortness of breath was not sufficiently sensitive also seems unlikely, since this scale was shown to be sensitive to either bronchodilation [12] or to bronchoconstriction [13] in patients with asthma or COPD. Finally, the small number of patients (estimated for a size effect of 25%) could be incriminated, but the difficulty of recruiting patients for this kind of study is obvious. Other groups have reported negative results with inhaled morphine. BEAUFORD et al. [14] found no effect of 1 to 10 mg nebulized morphine on dyspnoea assessed during an incremental exercise test in COPD patients. Similarly, MASOOD and co-workers [15, 16] reported that the dyspnoea/ventilation relationship during submaximal exercise is unaffected by nebulized morphine (10 or 25 mg) either in healthy subjects [15] or in patients with COPD [16]. HARRIS-EZE et al. [17] reached the same conclusion in patients with interstitial lung disease, for smaller 2.5 and 5 mg doses. Whilst we were unable to demonstrate any specific effect from nebulized morphine on dyspnoea, the present study showed a beneficial effect on dyspnoea from the four regimens being evaluated. Indeed, 101 of the 112 VAS ratings recorded during the study were positive, meaning the subjects felt less short of breath than at baseline, and the increase in rating over time was statistically significant. Oxygen via nasal prongs was included in the study protocol, as there is a theoretical potential for inhaled morphine to lower oxygen saturation. Although the effect of supplemental oxygen on dyspnoea at rest has been disputed [18], at least two studies have shown that oxygen reduces dyspnoea at rest to a greater extent than air (delivered in similar fashion) in hypoxaemic patients with COPD [19], or with terminal cancer [20]. In the present study, the beneficial effect on dyspnoea cannot be ascribed to oxygen, since an equal efficacy was obtained with 10 mg nebulized morphine, without the addition of oxygen. Our results suggest rather a placebo effect and/or a nonspecific effect, possibly mediated through a decrease in respiratory frequency. A placebo effect of similar magnitude on dyspnoea
5 NEBULIZED MORPHINE AND DYSPNOEA 1083 at rest has been demonstrated previously following nebulized saline in patients with severe asthma or COPD [7]. Other studies have provided arguments in favour of a nonspecific reduction in dyspnoea related to the use of either nasal prongs [18], or a face mask [21]. In conclusion, we have shown that 10 or 20 mg nebulized morphine, administered via a mouthpiece, combined with oxygen via nasal prongs, is not more effective than isotonic saline in relieving disabling dyspnoea in patients with advanced disease. This result is not unexpected, in view of several studies that have reported a lack of effect of nebulized morphine on exercise-induced dyspnoea in various populations [14 17], but is at variance with the description of a beneficial effect from inhaled opioids on dyspnoea at rest in a recent uncontrolled study [4]. Our patients benefited symptomatically from either saline or morphine, as a result of a placebo effect and/or a nonspecific effect from treatment. Our findings do not support the hypothesis that nebulized morphine, at a dose of 10 or 20 mg, has an intrapulmonary action of clinical relevance. Acknowledgements: The authors thank F. Martinez Vadillo for secretarial assistance. References 1. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in "pink puffers". Br Med J 1983; 286: Light RW, Muro JR, Sato RI, et al. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: Tooms A, McKenzie A, Grey H. Nebulised morphine. Lancet 1993; 342: Farncombe M, Chater S, Gillin A. The use of nebulized opioids for breathlessness: a chart review. Palliat Med 1994; 8: Bostwick DG, Null WE, Holmes S, et al. Expression of opioid peptides in tumors. N Engl J Med 1987; 317: Folstein MF, Folstein S, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: Noseda A, Schmerber J, Prigogine T, Yernault JC. Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J 1992; 5: Young IH, Daviskas E, Keena VA. Effect of low-dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989; 44: MacLeod RD, King BJ. Relieving breathlessness with nebulized morphine. Palliat Med 1995; 9: Davis CL. The use of nebulized opioids for breathlessness. Palliat Med 1995; 9: Chrubasik J, Wust H, Friedrich G, Geller E. Absorption and bioavailability of nebulized morphine. Br J Anaesth 1988; 61: Noseda A, Schmerber J, Prigogrne T, Yernault JC. How do patients with either asthma or COPD perceive acute bronchodilation? Eur Respir J 1993; 6: Noseda A, Schmerber J, Prigogine T, de Maertelaer V, Yernault JC. Perception of dyspnoea during acute changes in lung function in patients with either asthma or COPD. Respir Med 1995; 89: Beauford W, Saylor TT, Stansbury DW, Avalos K, Light RW. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest 1993; 104: Masood AR, Subhan MMF, Reed JW, Thomas SHL. Effects of inhaled nebulized morphine on ventilation and breathlessness during exercise in healthy men. Clin Sci 1995; 88: Masood AR, Reed JW, Thomas SHL. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 1995; 50: Harris-Eze AO, Sridhar G, Clemens E, et al. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med 1995; 152: Liss HP, Grant BJB. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 137: Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991; 143: Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic-terminal cancer patients. Lancet 1993; 342: Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987; 136:
The effect of opioid use on pulmonary function test in advanced COPD patients
The effect of opioid use on pulmonary function test in advanced COPD patients Parinaz Koohi Habibi Dehkordi (1) Sayed Mahdi Ayat (1) Hamid Rouhi Boroujeni (2) Hamid Sohrabpour (3) Abbas Fadaei (4) (1)
More informationLack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease
Eur Respir J 1997; 1: 227 2274 DOI: 1.1183/931936.97.11227 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 93-1936 Lack of effect of high doses of
More informationD yspnoea has been defined as a subjective sensation of
939 ORIGINAL ARTICLE A systematic review of the use of opioids in the management of dyspnoea A-L Jennings, A N Davies, J P T Higgins, J S R Gibbs, K E Broadley... See end of article for authors affiliations...
More informationA. Noseda*, J-P. Carpiaux*, J. Schmerber*, F. Valente**, J-C. Yernault***
Eur Respir J, 1994, 7, 279 285 DOI: 101183/090319369407020279 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 0903-1936 Dyspnoea and flow-volume curve
More informationBreathlessness in advanced disease. February 2017
Breathlessness in advanced disease February 2017 Breathlessness Managing breathlessness in primary care Chronic breathlessness Acute exacerbation of breathlessness Breathlessness at end of life Breathlessness
More informationNebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study
Vol. 29 No. 6 June 2005 Journal of Pain and Symptom Management 613 Clinical Note Nebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study Eduardo Bruera, MD, Raul Sala,
More informationDyspnea. Stephanie Lindsay
Dyspnea Stephanie Lindsay What is dyspnea? An unpleasant sensation of difficult, labored breathing Shortness of air Dyspnea is not the same as tachypnea therefore patients may not present with rapid breathing
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationAdverse effect of additional weight on exercise against gravity in patients with chronic obstructive airways disease
Thorax 1989;44:716-720 Adverse effect of additional weight on exercise against gravity in patients with chronic obstructive airways disease C R SWINBURN, B G COOPER, H MOULD, P A CORRIS, G J GIBSON From
More informationAPHN. Shortness of breath. Ednin Hamzah CEO, Hospis Malaysia.
APHN Shortness of breath Ednin Hamzah CEO, Hospis Malaysia ednin@hospismalaysia.org What is it? a subjective experience of difficult and uncomfortable breathing American Thoracic Society What do the patients
More informationShort burst oxygen therapy after activities of daily living in the home in chronic obstructive pulmonary disease
Thorax Online First, published on February 20, 2007 as 10.1136/thx.2006.063636 Short burst oxygen therapy after activities of daily living in the home in chronic obstructive pulmonary disease S J Quantrill,
More informationEffect of inhaled morphine on the development
596 Departnent of Respiratory Medicine, St Vincent's Hospital, Fitzroy, Victoria 3065, Australia R Leung P Hill J Burdon Correspondence to: Dr J Burdon. * Current address: Prince of Wales Hospital, Shatin,
More informationBREATHLESSNESS MANAGEMENT
Guideline Name: Breathlessness BACKGROUND Breathlessness is a common symptom in patients with cancer, end-stage heart failure and end-stage chronic obstructive pulmonary disease (COPD). There are many
More informationAsthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?
Registrar: LG PR RS Topic Asthma and COPD Asthma Tutorial Trainer MRW Date of Tutorial 18 th Jan 2007 Objectives of the tutorial How to diagnose What investigations and when Treatment guidelines QoF Criteria
More informationSam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation
Sam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation Trust Overview Which drugs? How much? How to give? Adverse
More informationThe adult with recurrent breathlessness. A/Prof Gerald Chua Medicine NTFGH
The adult with recurrent breathlessness A/Prof Gerald Chua Medicine NTFGH Dyspnoea Subjective experience of breathing discomfort Variable among individuals with apparently similar degrees of impairment
More informationOxygen Use in Palliative Care Guideline and Flowchart
Oxygen Use in Palliative Care Guideline and Flowchart Reviewed: October 2013 Gippsland Region Palliative Care Consortium Clinical Practice Group Policy. Title Keywords Ratified Oxygen Use in Palliative
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationManagement of acute asthma in children in emergency department. Moderate asthma
152 Moderate asthma SpO2 92% No clinical features of severe asthma NB: If a patient has signs and symptoms across categories, always treat according to their most severe features agonist 2-10 puffs via
More informationword, subject heading word, keyword heading word, protocol supplementary concept, rare
Online Supplement Appendix 1. Search strategies Medline: 1. Exp Oxygen Inhalation Therapy/ 2. Exp Oxygen/ 3. ((domicil* or home*) and oxygen).mp. [mp=title, abstract, original title, name of substance
More informationComparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD
Respiratory Medicine (2005) 99, 372 376 Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD P.J. Poole, R. Saini, S.M. Brodie, P.N. Black Department of Medicine,
More informationGestione della dispnea nell insufficienza respiratoria end-stage
Gestione della dispnea nell insufficienza respiratoria end-stage Salvatore M. Maggiore, MD, PhD salvatore.maggiore@unich.it Anesthesia and Intensive Care SS. Annunziata Hospital Gabriele d Annunzio University
More informationSupplementary Online Content
Supplementary Online Content Rahman NM, Pepperell J, Rehal S, et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationExacerbations. Ronald Dahl, Aarhus University Hospital, Denmark
1st WAO Allied Health Session - Asthma: Diagnosi Exacerbations Ronald Dahl, Aarhus University Hospital, Denmark The health professional that care for patients with asthma exacerbation must be able to Identificafy
More informationRegional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.
Regional Breathlessness Audit - Case te Survey 1. Introduction Please complete this form for your case note review. Cases used may be PROSPECTIVE AND/OR RETROSPECTIVE. Please log as many cases as you can.
More informationBronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Eur Respir J 2002; 20: 122 126 DOI: 10.1183/09031936.02.00264002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Bronchial reactions to the
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationManaging Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.
Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital. Things to consider: 1. Very common symptoms. 2. Can occur in any
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationThe Frequency and Correlates of Dyspnea in Patients with Advanced Cancer
.357 Journal of Pain and Symptom Management Vol. 19 No. 5 May 2000 Original Article The Frequency and Correlates of Dyspnea in Patients with Advanced Cancer Eduardo Bruera, MD, Bonnie Schmitz, RRT, James
More informationManagement of Dyspnea and Cough in Lung Cancer
Management of Dyspnea and Cough in Lung Cancer Dr. Chris Ogaranko Lung Cancer Educational Event November 2013 Presenter Disclosure Faculty: Dr. Chris Ogaranko Relationships with commercial interests: Grants/Research
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationDescriptors of Breathlessness in Patients With Cancer and Other Cardiorespiratory Diseases
182 Journal of Pain and Symptom Management Vol. 23 No. 3 March 2002 Original Article Descriptors of Breathlessness in Patients With Cancer and Other Cardiorespiratory Diseases Andrew Wilcock, DM, FRCP,
More informationNEBULISERS AND NEBULISED MEDICATION. A Guide for the use of nebulisers and nebulised medication in the community setting
NEBULISERS AND NEBULISED MEDICATION A Guide for the use of nebulisers and nebulised medication in the community setting Aim This guide has been developed from the generic guidance circulated in April 2014.
More informationDyspnea: Should we use BIPAP?
Dyspnea: Should we use BIPAP? Thomas R. Gildea MD, MS FCCP Head Section of Bronchoscopy Respiratory Institute Transplant Center Disclosure SuperDimension Inc. PI for single center study Others: Aeris,
More informationShort-burst oxygen immediately before and after exercise is ineffective in nonhypoxic COPD patients
Eur Respir J 2003; 22: 584 588 DOI: 10.1183/09031936.03.00027603a Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 CLINICAL FORUM Short-burst
More informationRelevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic
Topic: Prehospital use of bromide paired with salbutamol as treatment for shortness of breath. Author: Lisa Henderson Clinical Scenario: Two primary care paramedics respond code 4 for a 55 year old male
More informationKnowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital
ORIGINAL ARTICLE Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital ARM Fauzi, MRCP Kulliyah of Medicine, International Islamic
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationDyspnea: Evaluation and Management
Dyspnea: Evaluation and Management Sandra Whitlock, M.D. Four Seasons Palliative Care Course Handouts & Post Test o To download presentation handouts, click on the attachment icon o Presenter discloses
More informationPalliative care for heart failure patients. Susan Addie
Palliative care for heart failure patients Susan Addie Treatments The most common limiting and distressing complaint is of fatigue and breathlessness. Optimal treatment strategies relieve symptoms, improves
More informationFrequency of nocturnal symptoms in asthmatic children attending a hospital out-patient clinic
Eur Respir J, 1995, 8, 2076 2080 DOI: 10.1183/09031936.95.08122076 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Frequency of nocturnal
More informationPerformance, ventilation, and oxygen consumption in three different types of exercise test in patients with
Thorax 1985;40:581-586 Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease CR SWINBURN, JM WAKEFIELD, PW JONES From
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationPulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.
Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing
More informationRespiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
More informationA NEBULISERS AND NEBULISED MEDICATION. Generic Guide for the use of nebulisers and nebulised medication
A NEBULISERS AND NEBULISED MEDICATION Generic Guide for the use of nebulisers and nebulised medication Aim The aim of this guide is to provide a template for those who wish to develop their own nebuliser
More informationNIV - BI-LEVEL POSITIVE AIRWAY PRESSURE (BIPAP)
Introduction NIV - BI-LEVEL POSITIVE AIRWAY PRESSURE (BIPAP) Noninvasive ventilation (NIV) is a method of delivering oxygen by positive pressure mask that allows for the prevention or postponement of invasive
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationWF RESPIRATORY SYSTEM. RESPIRATORY MEDICINE
WF RESPIRATORY SYSTEM. RESPIRATORY MEDICINE 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect where possible 15 Classification.
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease By: Dr. Fatima Makee AL-Hakak () University of kerbala College of nursing Out lines What is the? Overview Causes of Symptoms of What's the difference between and asthma?
More informationDyspnea: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program
: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program Faculty / Presenter Disclosure Faculty: Dr. Lawrence Lee Relationships with commercial
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More information#8 - Respiratory System
Page1 #8 - Objectives: Study the parts of the respiratory system Observe slides of the lung and trachea Equipment: Remember to bring photographic atlas. Figure 1. Structures of the respiratory system.
More informationDevelopment of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)
954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and
More informationFarmaci inalatori e dispnea nell asma e nella BPCO. Federico Lavorini
Farmaci inalatori e dispnea nell asma e nella BPCO Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationOver the last several years various national and
Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American
More informationInterpreting Spirometry. Vikki Knowles BSc(Hons) RGN Respiratory Nurse Consultant G & W`CCG
Interpreting Spirometry Vikki Knowles BSc(Hons) RGN Respiratory Nurse Consultant G & W`CCG Why Spirometry? supports diagnosis classifies defect - obstructive/restrictive assesses -severity of defect -
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationSpirometry: FEVER DISEASE DIABETES HOW RELIABLE IS THIS? 9/2/2010 BUT WHAT WE PRACTICE: Spirometers are objective tools
SPIROMETRY PRINCIPLES, PROCEDURE AND QA Spirometry: Dr. Rahul Kodgule CHEST RESEARCH FOUNDATION, PUNE FEVER ISCHAEMIC HEART DISEASE DIABETES BUT WHAT WE PRACTICE: Spirometers are objective tools to diagnose
More informationCarole Wegner RN, MSN And Lori Leiser CRT
Airway Clearance Carole Wegner RN, MSN And Lori Leiser CRT Topics Suctioning and suctioning equipment Medications to facilitate t airway clearance Bronchial hygiene modalities Preparing for suctioning
More informationQuality Care Innovation lead clinician for integrated respiratory service georges ng* man kwong
Working in partnership Quality Care Innovation lead clinician for integrated respiratory service georges ng* man kwong chest physician pronounced ning qualified 1990 chief clinical information officer
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAir or oxygen as driving gas for nebulised salbutamol
Archives of Disease in Childhood, 1988, 63, 9-94 Air or oxygen as driving gas for nebulised salbutamol J G A GLEESON, S GREEN, AND J F PRICE Paediatric Respiratory Laboratory, Department of Thoracic Medicine,
More informationDr. A. Kerigan BREATHLESSNESS AT THE END OF LIFE
Dr. A. Kerigan BREATHLESSNESS AT THE END OF LIFE Faculty/Presenter Disclosure Faculty: Dr. A. Kerigan Relationships with commercial interests:* - Grants/Research Support: None - Speakers Bureau/Honoraria:
More informationUNIT TWO: OVERVIEW OF SPIROMETRY. A. Definition of Spirometry
UNIT TWO: OVERVIEW OF SPIROMETRY A. Definition of Spirometry Spirometry is a medical screening test that measures various aspects of breathing and lung function. It is performed by using a spirometer,
More informationCIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT
Circular Instruction 195 CIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT COMPENSATION FOR OCCUPATIONAL INJURIES
More informationBronchiectasis in Adults - Suspected
Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors
More informationSymptom Control in Heart Failure. Dr Claire L Hookey
Symptom Control in Heart Failure Dr Claire L Hookey Heart Failure symptoms Class III/IV CHF, mean 67.1 years, mean EF 22.3% Most prevalent symptoms:- lack of energy (66%) dry mouth (62%) shortness of breath
More informationYU DTW, Chan ACM, Poon MWY, Lau PMY. Physiotherapy Departments Kowloon Central Cluster
YU DTW, Chan ACM, Poon MWY, Lau PMY Physiotherapy Departments Kowloon Central Cluster Prevalence of Ca Lung and COPD Hong Kong Cancer Registry Hospital Authority Annual Report 2012-13 Breathlessness /
More information1 Chapter 13 Respiratory Emergencies 2 Respiratory Distress Patients often complain about. Shortness of breath Symptom of many different Cause can be
1 Chapter 13 Respiratory Emergencies 2 Respiratory Distress Patients often complain about. Shortness of breath Symptom of many different Cause can be difficult to determine. Even for physician in hospital
More informationBasic mechanisms disturbing lung function and gas exchange
Basic mechanisms disturbing lung function and gas exchange Blagoi Marinov, MD, PhD Pathophysiology Department, Medical University of Plovdiv Respiratory system 1 Control of breathing Structure of the lungs
More informationProblem Based Learning Session. Mr Robinson is a 67 year old man. He visits the GP as he has had a cough and fever for 5 days.
Problem Based Learning Session Mr Robinson is a 67 year old man. He visits the GP as he has had a cough and fever for 5 days. The GP takes a history from him and examines his chest. Over the left base
More informationCYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
More informationCystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically
More informationNebulised hypertonic saline for cystic fibrosis.
Revista: Cochrane Database Syst Rev. 2003;(1):CD001506. Nebulised hypertonic saline for cystic fibrosis. Autor: Wark PA, McDonald V. Source: Department of Respiratory Medicine, John Hunter Hospital, Locked
More informationBronchodilator Delivery and Nebuliser Trials in Adults
Bronchodilator Delivery and Nebuliser Trials in Adults Acute Management Favour the use of MDI (+/- Spacer) If considering nebuliser Short term treatment Approx. < 3 weeks See optimisation of inhaled bronchodilators
More informationAsthma Care in the Emergency Department Clinical Practice Guideline
Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely
More informationDear Reader, What was the study about? Why was the research needed? BI NCT
Dear Reader, Sponsors of clinical studies create study reports. A study report describes how the study was done and what the results of the study were. This is a summary of such a report. It is meant for
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationOxygen therapy for interstitial lung disease: a systematic review
REVIEW INTERSTITIAL LUNG DISEASE Oxygen therapy for interstitial lung disease: a systematic review Emily C. Bell 1, Narelle S. Cox 1,2,3, Nicole Goh 3,4,5, Ian Glaspole 5,6, Glen P. Westall 5,6, Alice
More informationChronic Obstructive Pulmonary Disease (COPD) Measures Document
Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationCOPD Challenge CASE PRESENTATION
Chronic obstructive pulmonary disease (COPD) exacerbations may make up more than 10% of acute medical admissions [1], and they are increasingly recognised as a cause of significant morbidity and mortality
More informationB reathlessness is the most disabling symptom associated
8 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease N J Stevenson, P M A Calverley... See end of article for
More information(To be filled by the treating physician)
CERTIFICATE OF MEDICAL NECESSITY TO BE ISSUED TO CGHS BENEFICIAREIS BEING PRESCRIBED BILEVEL CONTINUOUS POSITIVE AIRWAY PRESSURE (BI-LEVEL CPAP) / BI-LEVEL VENTILATORY SUPPORT SYSTEM Certification Type
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationAssessment of respiratory outcome among patients with lower respiratory tract disorders
2018; 4(11): 196-200 ISSN Print: 2394-7500 ISSN Online: 2394-5869 Impact Factor: 5.2 IJAR 2018; 4(11): 196-200 www.allresearchjournal.com Received: 03-09-2018 Accepted: 04-10-2018 Surendran SR M.Sc (Medical
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More information